Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Kidney and Transplant

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events · patients on HD with HCV infection

Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.1 [1.01, 1.19]
1 study · 377 participants
Low

Treatment adverse events: UTI/pyelonephritis · kidney transplant recipients: first rejection episode

Rituximab (B cell) + steroid probably leads to higher treatment adverse events: UTI/pyelonephritis compared with steroid alone (moderate certainty).

1 finding from 1 review